Imepitoin (Pexion) for Canine Idiopathic Epilepsy: Evidence Review

Bottom line

• Imepitoin (Pexion) is a low-affinity partial agonist at the benzodiazepine receptor, EMA-approved in dogs (not cats) for reducing the frequency of generalised seizures due to idiopathic epilepsy. [1]
• In the pivotal canine non-inferiority field trial (n=226), mean generalised seizure frequency fell to ~1.1/month on both imepitoin and phenobarbital; 47% of imepitoin-treated evaluable dogs were seizure-free at 12 weeks versus 58% on phenobarbital. [1]
• The chief clinical differentiator is safety, not raw efficacy: versus phenobarbital, imepitoin produced less polyuria (10% vs 19%), polydipsia (14% vs 23%), and marked sedation (14% vs 25%), with no hepatic enzyme elevations and no required liver monitoring. [1]
• Imepitoin is explicitly NOT recommended as primary treatment for cluster seizures or status epilepticus, and its efficacy as add-on therapy has not been demonstrated — these were not investigated in the pivotal trials. [1]
• Off-label feline use now has one multicentre RCT (Charalambous 2026, n=37): imepitoin reached a 62% responder rate (seizures 6.1→3.0/month, P=0.028) versus 90% for phenobarbital, with a high 88% adverse-effect rate (ataxia, elevated ALT). [3]

Drug facts

• Class: Novel antiepileptic; imidazolinone derivative.
• Mechanism: Low-affinity partial agonist at the benzodiazepine site of the GABA_A receptor, potentiating GABA_A-mediated neuronal inhibition; a weak calcium-channel-blocking effect may contribute. Because it is a partial (not full) agonist, a theoretical ceiling limits both maximal efficacy and the degree of sedation relative to classic benzodiazepines. [1] The Charalambous feline trial additionally characterises imepitoin as a high-affinity PDE10A inhibitor, a mechanistic point distinguishing it from the barbiturate phenobarbital. [3]
• Route/interval: Oral; twice daily approximately 12 hours apart. [1]
• Indication (label): Reduction of the frequency of generalised seizures due to idiopathic epilepsy in dogs; also approved for noise-aversion/phobia-related anxiety in dogs. [1]
• Approval: EMA first authorisation 25 February 2013; EU/2/12/147, marketing authorisation holder Boehringer Ingelheim Vetmedica GmbH. [1]
• Contraindications (label): Hypersensitivity to imepitoin; severe hepatic impairment; severe renal or cardiovascular disorders. [1]
• Common adverse effects (label): Polyphagia (very common, especially at initiation); hyperactivity, polyuria, polydipsia, somnolence, hypersalivation, emesis, ataxia, apathy, and diarrhoea — mild and generally transient. [1]

Efficacy in dogs with idiopathic epilepsy

Pivotal dose-finding RCT (Rundfeldt, Tipold & Löscher 2015)

Rundfeldt et al. ran a multicentre, double-blind, randomised controlled field trial at nine European veterinary neurology referral centres, enrolling 127 dogs with newly diagnosed idiopathic epilepsy. Dogs were randomised 1:1 to high-dose or low-dose imepitoin for a 12-week blinded phase, followed by a 12-week open-label continuation on the high dose. [2]

Monthly seizure frequency dropped significantly more in the high-dose group: a mean reduction of 1.7 (± 2.8) seizures/month versus 0.8 (± 2.0)/month for low dose (P=0.044). During the blinded phase, 37.5% of high-dose and 31.7% of low-dose dogs became seizure-free; the between-group difference was not significant, reflecting a higher baseline seizure burden in the high-dose arm by randomisation. When low-dose dogs were stepped up to the high dose in the open-label phase, the seizure-free rate rose to 46.8% (22 of 47 dogs). Crucially, antiepileptic activity did not wane over 6 months of continuous high-dose treatment, indicating no tolerance development in a clinical setting. [2]

Non-inferiority comparison with phenobarbital (EMA Pexion SPC)

The pivotal European field trial supporting EU marketing authorisation compared imepitoin with phenobarbital in 226 dogs with newly diagnosed idiopathic epilepsy. After excluding non-responders (45% of the imepitoin group vs 20% of the phenobarbital group), mean generalised seizure frequency fell from 2.3/month at baseline to 1.1/month after 20 weeks in the imepitoin group, mirroring the same reduction in the phenobarbital group. The between-group difference in seizure frequency was 0.004 (95% CI −0.928, 0.935), meeting the pre-specified non-inferiority margin. During the 12-week evaluation phase, 47% of imepitoin-treated evaluable dogs and 58% of phenobarbital-treated evaluable dogs were free of generalised seizures. [1]

Synthesis (canine efficacy)

The two data sets are consistent: imepitoin delivers a clinically meaningful reduction in generalised seizure frequency and, in the evaluable (responder) population, is non-inferior to phenobarbital on monthly seizure frequency. [1] The important caveat is at the front end of therapy — imepitoin has a higher initial non-response rate than phenobarbital (~45% vs ~20%), so the seizure-free proportion trends numerically lower (47% vs 58%). This positions imepitoin as an alternative first-line agent for generalised idiopathic epilepsy rather than a universally superior one, with the decision driven mainly by the safety trade-off below. [1]

Comparators: imepitoin vs phenobarbital adverse-event profile

Where efficacy is broadly comparable in responders, the adverse-event profile is the decisive differentiator. In the EMA-submitted controlled comparison (safety population 116 imepitoin, 110 phenobarbital), rising phenobarbital doses were associated with increases in all five monitored liver enzymes (ALT, AP, AST, GGT, GLDH); none of the five rose with increasing imepitoin doses. Fewer adverse events were reported on imepitoin than phenobarbital for polyuria (10% vs 19%), polydipsia (14% vs 23%), and marked sedation (14% vs 25%). [1]

Because imepitoin's mechanism is partial agonism, there is no ceiling-dose hepatotoxicity concern of the type seen with phenobarbital, and no routine liver-enzyme monitoring is required — a meaningful compliance advantage. [1] The clinical corollary, seen across the canine data, is that the numerically lower seizure-free rate means dogs with a high seizure burden or a history of cluster events may still need phenobarbital or combination therapy. All antiseizure-medication selection and monitoring should follow current ACVIM/ECVIM consensus guidance and the approved label. [1]

Safety, adverse reactions & pharmacokinetics

CNS and systemic adverse reactions. In the Rundfeldt 2015 study, CNS-related adverse reactions were predominantly ataxia, disorientation, hyperactivity, and restlessness; these were transient, occurred mainly in the first weeks of treatment, and resolved with continued dosing. No hepatic enzyme increases and no other organ toxicity were observed; a marginal creatinine rise stayed within the normal range. [2] The label lists polyphagia as a very common reaction at initiation; mild elevations of plasma creatinine and cholesterol may occur but remain within reference ranges. Aggression has been uncommonly reported post-marketing and may be treatment-related or peri-ictal. [1]

Pharmacokinetics. Imepitoin is well absorbed orally (bioavailability >92%), reaching peak blood concentrations at ~2 hours; food reduces AUC by ~30% without affecting Tmax or Cmax. Elimination half-life is ~1.5–2 hours, and the drug is predominantly excreted via faeces, so PK accumulation is not expected in renally impaired dogs. Experimental models up to 4 weeks show no tolerance development. [1]

Off-label feline use: what the evidence supports

Imepitoin is not licensed for cats. Feline use is off-label, and — as of July 2026 — there is no antiseizure drug licensed for cats in Europe, which is precisely the gap the recent feline trial addresses. [3]

Feline idiopathic epilepsy (Charalambous 2026 multicentre RCT)

Charalambous M et al. published the first multicentre, single-blinded, randomised, placebo-controlled trial of imepitoin versus phenobarbital in 37 cats with idiopathic epilepsy, over a 15-week window (Front Vet Sci 2026;13:1770972). [3] Key results:

• Imepitoin: 62% responder rate (>50% reduction in monthly seizure frequency); mean monthly seizure frequency fell from 6.1 to 3.0 (P=0.028); adverse effects in 88% of cats, predominantly ataxia and elevated ALT.
• Phenobarbital: 90% responder rate, with significant reductions in seizure frequency (P=0.0026) and seizure days (P=0.0011), and a significantly longer time to first post-treatment seizure than both imepitoin and placebo.
• Between-group: seizure-day reduction was significantly greater for phenobarbital than imepitoin (P=0.036), but responder rate (P=0.1) and overall seizure-frequency reduction (P=0.13) did not differ significantly.

Synthesis: phenobarbital appears the more potent feline antiseizure option (superior on seizure-day reduction and time-to-first-seizure), consistent with decades of clinical experience, while imepitoin delivers a clinically meaningful but second-tier effect. [3] The feline adverse-effect signal (88% rate, dominated by ataxia and elevated ALT) differs from the canine profile — notably, ALT elevation appears in cats whereas the canine controlled data showed no hepatic enzyme rise on imepitoin. [1][3] For clinicians already using imepitoin off-label in cats, this RCT supplies the first randomised reference point for expected responder rates and adverse events against the phenobarbital standard. [3]

Feline veterinary-visit stress (Agan 2026 pilot) — early signal only

A separate, much earlier-stage line of feline evidence explores imepitoin for visit-related stress. Agan et al. (Vet Sci 2026;13(5):431) ran an open-label pilot in 32 cats (n=16/group) randomised to a single oral imepitoin dose or placebo before veterinary visits. Salivary cortisol showed a significant differential decrease favouring imepitoin, and heart rate fell more from pre- to post-treatment despite a higher imepitoin-group baseline; behavioural scores (Cat Stress Score, Cat Examination Response Scale) also improved. [4]

Interpretation: the physiological findings are biologically plausible given GABA_A potentiation, but the open-label design, single-investigator assessment, and small size (wide effect-size confidence intervals, acknowledged observer bias) sharply limit interpretability. The authors themselves call for larger, blinded, methodologically robust trials before clinical application. Treat this as a very early candidate-indication signal, not a basis for practice change; gabapentin remains the best-studied pre-visit anxiolytic in cats. [4]

Contraindications, precautions & PK

• Contraindicated in hypersensitivity to imepitoin and in severe hepatic, renal, or cardiovascular disease. [1]
• Not for primary management of cluster seizures or status epilepticus (not studied); add-on efficacy is not established. [1]
• Transition carefully: the label advises a gradual switch when changing from another antiseizure drug. [1]
• PK reassurance: faecal-predominant elimination means accumulation is not expected in renal impairment; short (~1.5–2 h) half-life supports twice-daily dosing. [1]
• Feline caution: off-label only; the one feline epilepsy RCT reports an 88% adverse-effect rate including ALT elevation, so hepatic monitoring is prudent when used in cats despite the canine "no liver monitoring" position. [1][3]

Practical decision support

• Reach for imepitoin (dogs) when phenobarbital's polyuria/polydipsia/polyphagia, sedation, or hepatic-monitoring burden is limiting welfare or owner compliance, in a dog with generalised idiopathic epilepsy and no cluster/status history. Set owner expectations for polyphagia at onset and transient CNS signs (ataxia, restlessness) in the first weeks that resolve with continued dosing; confirm that routine liver-enzyme monitoring is not required. [1][2]
• Favour phenobarbital (or combination) when seizure burden is high, cluster seizures or status epilepticus have occurred, or a maximal seizure-free probability is the priority — reflecting its higher intrinsic GABA_A efficacy and larger seizure-free proportion. [1]
• In cats (off-label), imepitoin is a reasonable option when phenobarbital is not preferred (sedation, hepatotoxicity-monitoring concerns), but counsel owners that phenobarbital outperformed it on seizure-day reduction in the only RCT, and monitor ALT given the observed feline hepatic signal. [3]
• Do not yet use imepitoin for feline visit anxiety outside a study context; the evidence is a single open-label pilot. [4]

Frequently Asked Questions

(rendered from the FAQ metadata)

Changelog

• 2026-06-07: First published (canine evidence review).
• 2026-07-06: Consolidated into evergreen hub. Folded in four dated dispatches — the canine imepitoin-vs-phenobarbital adverse-event dispatch (2026-06-14) and three feline dispatches (2026-06-08, 2026-06-13, 2026-06-19). The Charalambous 2026 feline epilepsy RCT (cited across three of those spokes under both PMC12921493 and PMID 41728120) was verified as one study and deduplicated to a single citation [3]. Added feline off-label sections (idiopathic epilepsy RCT; visit-stress pilot [4]). Corrected the Rundfeldt/Tipold/Löscher 2015 citation to its verified journal, BMC Veterinary Research (a spoke had mislabelled it J Vet Intern Med). All four citations verified against PMC/EC sources on 2026-07-06.